Regional comparison of efficacy and safety for vilobelimab in critically ill, invasively mechanically ventilated COVID-19 patients

Background Vilobelimab, a first in class C5a-specific monoclonal antibody, improved 28-day and 60-day mortality in intubated COVID-19 patients in PANAMO, a phase 3 randomised, double-blind, placebo-controlled multicentre study. All-cause mortality was pre-specified to be analysed pooling by region (...

Full description

Saved in:
Bibliographic Details
Main Authors: Gernot Marx, Antoine Roquilly, Tobias Welte, Jean Dellamonica, Greet Hermans, Martin Witzenrath, Michael Bauer, Matthias Gründling, Ulrich Jaschinski, Robert Zerbib, Djillali Annane, Matthijs C Brouwer, Bruno Mourvillier, Jean Baptiste Lascarrou, Francis Schneider, Guillaume Thiéry, Diederik van de Beek, Carole Schwebel, Fabio S. Taccone, Luc Desmedt, Claire Dupuis, Pieter van Paassen, Michael Piagnerelli, Endry H T Lim, Sanne de Bruin, Simon Rückinger, Claus Thielert, Renfeng Guo, Bruce P Burnett, Camilla Chong, Niels C Riedemann, Alexander P Vlaar, Alexander P. J. Vlaar, Leo M. A. Heunks, Endry H. T. Lim, Matthijs C. Brouwer, Pieter R. Tuinman, José Francisco K. Saraiva, Suzana M. Lobo, Rodrigo Boldo, Jesus A. Simon-Campos, Alexander D. Cornet, Anastasia Grebenyuk, Johannes M. Engelbrecht, Murimisi Mukansi, Philippe G. Jorens, Korinna Pilz, Niels C. Riedemann, Pierre Bulpa, Marc Diltoer, Nikolaas De Neve, Antonio T. Freire, Felipe D. Pizzol, Anna Karolina Marinho, Victor H. Sato, Clovis Arns da Cunha, Mathilde Neuville, Jean Luc Diehl, Jean Paul Mira, Marc Berger, Klaus Matschke, Roberto Mercado-Longoria, Belinda Gomez Quintana, Jorge Alberto Zamudio-Lerma
Format: Article
Language:English
Published: BMJ Publishing Group 2025-04-01
Series:BMJ Open Respiratory Research
Online Access:https://bmjopenrespres.bmj.com/content/12/1/e002206.full
Tags: Add Tag
No Tags, Be the first to tag this record!